Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
Atomoxetine is indicated for:
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older and in adolescents as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician or child/adolescent psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and atomoxetine should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Atomoxetine is contraindicated in the following cases: